Effects of eight weeks of 6-OXO supplementation on serum hormone profiles and on serum and urinary clinical safety markers in resistance-trained males.

Includes bibliographical references (p. 64-69).The purpose of this study was to determine the effects of 6-OXO, an aromatase inhibitor, in a dose dependent manner on serum hormone levels and clinical safety markers in resistance trained males. Sixteen healthy trained subjects, who participated in a resistance training protocol, had blood samples taken at weeks 0, 1, 3, 8, and 11. These samples were analyzed for total testosterone, free testosterone, DHT, estradiol, estriol, estrone, SHBG, LH, FSH, GH, and cortisol. There were no significant differences between groups (p>0.01). However, total testosterone concentration, free testosterone concentration, and DHT concentration increased over the course of the study (p=0.009). Measures of body composition did not change with supplementation (p>0.05). Safety markers were seen to not be adversely affected with ingestion of 6-OXO (p>0.01). 6-OXO supplementation appears to be safe and increases total testosterone, free testosterone, and DHT concentrations independent of the two different doses.by Daniel A. Rohle.M.S.Ed

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop

Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC(2)) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology

The Molecular Taxonomy of Primary Prostate Cancer

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defectsclose